期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 88, 期 2, 页码 198-200出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2017.03.011
关键词
Cefiderocol; S-649266; Quality control; M23; Siderophore cephalosporin
资金
- Shionogi & Co., Ltd. (Osaka, Japan)
- Allergan
- Astellas
- Cubist Pfizer
- Cempra
- Theravance
Cefiderocol (formerly S-649266) is a new catechol-substituted parenteral siderophore cephalosporin with potent in vitro antibacterial activity against Gram-negative isolates including multidrug-resistant strains. A recent study following CLSI M23-A4 quality control guidelines established cefiderocol MIC QC ranges against Escherichia coil ATCC 25922 (0.06-0.5 mu g/mL) and Pseudomonas aeruginosa ATCC 27853 (0.06-0.5 mu g/mL). (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据